Heterogeneous Or Solid Phase Assay System (e.g., Elisa, Etc.) Patents (Class 435/7.92)
  • Patent number: 11280785
    Abstract: A device and method for use in capturing a substance in a liquid, by feeding the liquid through a capturing device including: a lateral capillary flow matrix and a capturing matrix in fluid communication with the lateral capillary flow matrix so as to produce two lateral flows sufficient to impart transverse oscillations to the lateral flow in the capturing matrix, such oscillations driving the liquid into the interior of the capturing matrix thereby exposing its interior to the liquid.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: March 22, 2022
    Assignee: RealBio Technologies Ltd.
    Inventors: Avraham Reinhartz, Sara Alajem
  • Patent number: 11273455
    Abstract: The present invention relates to a method of dewatering post fermentation fluids in a starch to ethanol process. More particularly the invention relates to use of a nuclease enzyme for separation of whole stillage into an insoluble fraction and a supernatant fraction. In a specific embodiment the present invention relates to a method of dewatering whole stillage comprising the steps of: i) subjecting whole stillage to one or more nuclease enzymes; ii) separating the material into an insoluble fraction and a supernatant fraction.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: March 15, 2022
    Assignee: NOVOZYMES A/S
    Inventor: Feng Xu
  • Patent number: 11269825
    Abstract: Disclosed herein are system, method, and computer program product embodiments for performing a database migration with automatic privilege retention and restoration. Embodiments provide for migrating a source database object at a source database to a target database object at a target database. The embodiments provide for binding a retention tag to database objects in order to mark the objects whose privileges are to be retained during a database migration. This approach enables privileges of database objects that are involved in a database migration to be automatically restored at target database objects after the migration.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: March 8, 2022
    Assignee: SAP SE
    Inventor: Reinhard Arlt
  • Patent number: 11262348
    Abstract: The present invention relates to cell-based methods for screening body fluids or tissues for factors that prevent cellular uptake of lysosomal enzymes, including neutralizing factors such as neutralizing antibodies, that arise as a result of lysosomal enzyme replacement therapy.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: March 1, 2022
    Inventors: Andrew Melton, Stephen Zoog, Lynne Jesaitis
  • Patent number: 11237175
    Abstract: The present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy. Finally, the invention concerns a kit comprising means for detecting at least two proteins selected from the group consisting of heparan sulfate proteoglycan core protein or fragments thereof, carbonic anhydrase 1, prothrombin or fragments thereof, tetranectin, CD59 glycoprotein, plasma serine protease inhibitor, mannan-binding lectin serine protease 2 or isoforms thereof, antithrombin-III, alpha-1-antitrypsin, collagen alpha-1(I) chain, alpha-enolase, histone H2B type 1-O, glutaminyl-peptide cyclotransferase, protein AMBP and zinc-alpha-2-glycoprotein.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: February 1, 2022
    Inventors: Claude Granier, Franck Molina, Nicolas Salvetat, Laurence Molina, Randa Siala, Eric Renard
  • Patent number: 11230735
    Abstract: The present disclosure relates to methods of characterizing disease. In particular, this invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects suffering from sepsis, based on the characterization of genes associated with a reactive oxygen species (ROS) molecular signature.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: January 25, 2022
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Louise Hecker, Marvin J. Slepian, Christian Bime, Tong Zhou, Ting Wang
  • Patent number: 11208693
    Abstract: The present disclosure provides methods and systems directed to cell-free identification and/or monitoring of pregnancy-related states. A method for identifying or monitoring a presence or susceptibility of a pregnancy-related state of a subject may comprise assaying a cell-free biological sample derived from said subject to detect a set of biomarkers, and analyzing the set of biomarkers with a trained algorithm to determine the presence or susceptibility of the pregnancy-related state.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: December 28, 2021
    Assignee: Mirvie, Inc.
    Inventors: Maneesh Jain, Eugeni Namsaraev, Morten Rasmussen, Joan Camunas Soler, Farooq Siddiqui, Mitsu Reddy
  • Patent number: 11169160
    Abstract: The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3).
    Type: Grant
    Filed: May 23, 2015
    Date of Patent: November 9, 2021
    Inventors: Peter Schwind, Ariane Caesar
  • Patent number: 11154857
    Abstract: A single-channel, chemical-immunological hybrid biosensor is disclosed. According to an embodiment, the hybrid biosensor includes a reaction strip 100 in the form of a porous membrane through which a sample 1 moves by capillary action. the reaction strip 100 is in the form of a porous membrane through which the sample 1 moves by capillary action. Biomarkers in the sample 1 are independently detected based on a chemical reaction and binding reactions on the reaction strip 100.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: October 26, 2021
    Inventor: Se-Hwan Paek
  • Patent number: 11150252
    Abstract: Disclosed is a method for measuring phosphorylated tau protein in a biological sample collected from a subject, comprising the steps of: preparing a measurement sample containing a non-capture bead and a capture bead to which an immune complex is bound, by forming the immune complex of the phosphorylated tau protein in the biological sample, a capture antibody and a detection antibody on the capture bead, in the presence of the non-capture bead; and detecting a signal derived from the immune complex in the measurement sample.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 19, 2021
    Assignees: SYSMEX CORPORATION, National Institutes for Quantum and Radiological Science and Technology
    Inventors: Takahiko Tokuda, Harutsugu Tatebe
  • Patent number: 11135591
    Abstract: A test tube including an annular body having an open proximal end and a closed distal end, and an longitudinal member in a distal portion of an interior of the annular body, the longitudinal member is substantially parallel to a central longitudinal axis of the annular body and is connected to an internal surface of the distal portion of the annular body.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: October 5, 2021
    Inventors: Snir Zano, Daniel Gurevich
  • Patent number: 11136581
    Abstract: Contact of endothelial cells with inhibitors of inhibin and/or the alpha subunit of inhibin can be utilized to modify the activity of endothelial cell expression products including SMAD 1/5. Methods can also include inhibiting Alk1 and/or endoglin as components of inhibin-activated pathway of SMAD 1/5 signaling. Methods can be combined with other anti-angiogenesis therapies such as anti-VEGF therapies. Methods can be utilized in treatment of inhibin-expressing cancers (e.g., ovarian cancer, pancreatic cancer) as well as other pathologies such as preeclampsia and PCOS.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 5, 2021
    Assignee: University of South Carolina
    Inventors: Mythreye Karthikeyan, Priyanka Singh
  • Patent number: 11131667
    Abstract: The present disclosure provides a paper-based vertical flow test platform including: a detection portion; a movable conjugation portion having an enzyme-labelled protein; and an absorbent portion. The present disclosure further provides a detection method by using the same. With the folding and sliding design, the present disclosure can reduce the volume of specimen fluids used, and prevent the interference problem. Also, a portable diagnostic test platform is provided with ease of use, lower cost, higher sensitivity and longer storage period to meet requirements of point-of-care for the fast, simple and stable detection.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: September 28, 2021
    Assignee: National Taiwan University
    Inventors: Chien-Fu Chen, Wen-Shin Yeh
  • Patent number: 11112366
    Abstract: A reagent for enhancing a chemiluminescent reaction includes luminol or luminol derivatives, an oxidant, an electron mediator, and an enhancer. The enhancer is a nitrogen-containing fused heterocyclic compound having at least two nitrogen atoms. The present disclosure further provides a kit for enhancing a chemiluminescent reaction comprising the foregoing reagent.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: September 7, 2021
    Inventors: Chih-Ching Huang, Chia-Wen Lien
  • Patent number: 11079396
    Abstract: A method is provided for determining the presence of soluble, misfolded ?-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric ?-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded ?-synuclein aggregate is present in the biological sample.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: August 3, 2021
    Assignee: Amprion, Inc.
    Inventors: Luis Concha, Carly Farris, Bret Holguin, Russell Lebovitz, Benedikt Vollrath, Frank Espin
  • Patent number: 11062828
    Abstract: Provided is a color encoding method including providing a composition including a liquid medium and magnetic nanoparticles dispersed in the liquid medium; applying a magnetic field to the composition to align the magnetic nanoparticles; and applying a patterned energy source to the composition to solidify the composition, wherein more than one region of the composition are sequentially solidified with varying magnetic field strength to fix a plurality of color codes.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: July 13, 2021
    Inventors: Sunghoon Kwon, Howon Lee, Junhoi Kim, Hyoki Kim
  • Patent number: 11061028
    Abstract: This disclosure provides antigen compositions useful for diagnosing Lyme disease and for detecting antibodies that bind to Borrelia antigens. The antigenic compositions comprise a mixture of hybrid peptides and Borrelia proteins. This disclosure also provides devices, methods, and kits that are useful for diagnosing Lyme disease and for detecting anti-Borrelia antibodies in a sample to aid in the diagnosis of Lyme disease.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: July 13, 2021
    Assignee: Defined Diagnostics, LLC
    Inventors: Nina Lukinova, Xiaoling Song, Paul Francis Macomber, Jill Ann White
  • Patent number: 11053266
    Abstract: Disclosed herein are caged haptens and caged hapten-antibody conjugates useful for enabling the detection of targets located proximally to each other in a sample.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: July 6, 2021
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Yuri Belosludtsev, Traci D. DeGeer, Wendy J. French, Junshan Hao, Brian Daniel Kelly, Adrian Murillo, Nathan Walter Polaske
  • Patent number: 11046734
    Abstract: Provided herein are chimeric polypeptides that may be used, e.g., for the diagnosis of or vaccination against Ehrlichia chaffeensis and/or Ehrlichia canis.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: June 29, 2021
    Assignee: Research Development Foundation
    Inventors: Jere W. McBride, David H. Walker
  • Patent number: 11045451
    Abstract: Materials and methods for detecting and treating Coccidioidomycosis (Valley Fever) are provided herein. For example, materials and methods for enriching and detecting biomarker antigens (e.g., polypeptides and/or glycans) from Coccidioides immitis and Coccidioides posadasii, the fungi that cause Valley Fever, are described herein, as are methods for treating an individual for Valley Fever based on the results of the described detection methods.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: June 29, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Thomas E. Grys, Douglas Lake, Natalie Michelle Mitchell
  • Patent number: 11029314
    Abstract: A method for diagnosis of IgA nephropathy is provided using a combination of alpha-1B-glycoprotein (A1BG) or a truncated fragment thereof having a molecular weight of 13-60 kDa, orosomucoid 1 (ORMI), and Ig lambda-2 chain C regions (IGLC2) as protein markers in a urine sample from a subject.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: June 8, 2021
    Inventors: Krzysztof Mucha, Leszek Paczek, Radoslaw Zagozdzon, Bartosz Foroncewicz, Michal Dadlez, Magdalena Bakun, Jan Piwowarski, Tomas Pilzys, Michal Marcinkowski, Damian Garbicz, Elzbieta Grzesiuk, Michal Florczak
  • Patent number: 11015220
    Abstract: Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the conjugate has polymerase activity. Such conjugates can exhibit reduced aggregation and improved stochiometries wherein the average biomolecule:nanoparticle ratio approaches or equals 1:1. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: May 25, 2021
    Assignee: Life Technologies Corporation
    Inventors: Theo Nikiforov, Daniel Mazur, Xinzhan Peng, Tommie Lloyd Lincecum, Yuri Belosludtsev, Howard Reese, Dmitriy Gremyachinskiy, Roman Rozhkov, John Mauro, Joseph Beechem, Eric Tulsky, Imad Naasani, Kari Haley, Joseph Treadway
  • Patent number: 10988519
    Abstract: Provided herein is a recombinant viral vector having packaged therein an expression cassette comprising an engineered complement regulator factor H (fH), wherein the gene encodes a hfH protein variant comprising short consensus repeats (SCRs) 1-4, 6-8, and 17-20. Pharmaceutical compositions containing this vector and plasmids comprising nucleic acid sequences that encode the fH protein variant are also provided.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 27, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Wenchao Song, Damodar Gullipalli, Takashi Miwa
  • Patent number: 10928288
    Abstract: A method of monitoring an immunoassay comprises determining the shape of the flow edge of fluid across an immunoassay region. This allows, for example, early detection of possible errors in the test. The above methods may also be used to provide methods to improve the run conditions of a test during its development. The method may be applied to a competitive assay.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: February 23, 2021
    Inventors: Timothy John Abbott, David Patrick Edward Brookes
  • Patent number: 10921321
    Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens. The peptide compositions comprise polypeptide sequences comprising variants in the IR6 domain of the Borrelia VlsE protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Borrelia antigens and the diagnosis of Lyme disease.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: February 16, 2021
    Assignee: Abaxis, Inc.
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile, Jeremy Walker, Cristina Cuesico
  • Patent number: 10921324
    Abstract: Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: February 16, 2021
    Inventors: Victoria Lunyak, James Robert Tollervey
  • Patent number: 10900959
    Abstract: The disclosure relates to a method for quantitatively measuring concentration in an aqueous solution of a water soluble polymer that is functionalized with at least one tracer, wherein the method involves impregnating a flow assay with a test area, introducing the flow assay into a test reader, and using the test reader to compare test data to a calibration curve so as to determine the concentration of the water-soluble polymer. This method allows the determination of residuals concentration in aqueous solution recovered from different industries, including oil and gas produced water, mining fluids, industrial water systems, and water treatment applications.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: January 26, 2021
    Assignee: S.P.C.M. SA
    Inventors: Kimberley MacEwen, Hisham El-Shaffey, Michael Skriba
  • Patent number: 10883961
    Abstract: A detecting method for blood is provided. The method includes the following steps. A sensing device including a base and at least one response electrode is provided, wherein the response electrode is spaced apart from a gate end of the base. Blood including blood cells and targets is disposed on the response electrode. The blood is separated into a first part and a second part, wherein the first part is in contact with the response electrode, and the blood cell count in the first part is less than that in the second part. A voltage is applied on the response electrode, such that an electric field is generated between the response electrode and the gate end of the base, and a detection current generated from the base is measured to detect a characterize of the targets.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: January 5, 2021
    Assignee: National Tsing Hua University
    Inventors: Yu-Lin Wang, Indu Sarangadharan, Shin-Li Wang
  • Patent number: 10875908
    Abstract: The invention relates to an anti-human p53 antibody suitable for specifically binding a linear epitope which is exposed only in a conformationally altered isoform of the characteristic p53 protein of patients with Alzheimer's disease or prone to develop Alzheimer's disease or cognitive impairment during ageing. Methods and diagnostic and prognostic kits are also described.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 29, 2020
    Assignee: DIADEM S.R.L.
    Inventors: Maurizio Memo, Daniela Uberti
  • Patent number: 10866229
    Abstract: A system for molecular mapping includes a semiconductor substrate defining a reservoir to receive a sample of molecules and a nanofluidic channel in fluid communication with the reservoir. The system also includes a plurality of electrodes, in electrical communication with the nanofluidic channel, to electrophoretically trap the sample of molecules in the nanofluidic channel. At least one avalanche photodiode is fabricated in the semiconductor substrate and disposed within an optical near-field of the nanofluidic channel to detect fluorescence emission from at least one molecule in the sample of molecules.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: December 15, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Huaiyu Meng, Rajeev Ram
  • Patent number: 10828507
    Abstract: A system (30) and method for detecting or predicting toxicity induced by radiation therapy. A device (34) is configured for determining polypeptide biomarkers present in a urine sample. At least one processor (36) is programmed to detect or predict radiation toxicity based on one or more polypeptide biomarkers determined to be in the urine sample.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 10, 2020
    Assignee: Koninklijke Philips N.V.
    Inventors: Carolina Ribbing, Katrin Bitter
  • Patent number: 10830727
    Abstract: The application relates to an electrode for use in the electrochemical detection of a target species, wherein the electrode has a planar surface disposed on which are probe molecules that are capable of binding selectively to the target species, wherein the electrode, prior to binding of the probe molecules with the target species, has an electron transfer resistance per area of the electrode of from 10 megaohms cm?2 to 95 megaohms cm?2.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: November 10, 2020
    Assignees: Universidade Estadual Paulista “Julio de Mequita Filho”, Oxford University Innovation Limited
    Inventors: Jason Davis, Paulo Roberto Bueno
  • Patent number: 10823739
    Abstract: The present invention provides novel peptides, compositions, and methods for creating quantitative novel compositions, as well as methods for creating quantitative standards to calibrate analytes. These peptides, compositions, and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers (e.g., Tau). Also provided are kits comprising the peptides or compositions described herein, for use in assays (e.g., sandwich immunoassays).
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: November 3, 2020
    Inventors: Paul Rhyne, Adam J. Simon, Flora Berisha, Robert John Neely, Christopher J. Spedaliere, Claudio Mapelli
  • Patent number: 10753952
    Abstract: The present invention provides a rapid, sensitive method for forensic drug testing in a post-mortem subject or a live or a post-mortem animal using oral fluid collected from the post-mortem subject or live or post-mortem animal. The method comprises collecting a sample of oral fluid from a post-mortem subject or a live or a post-mortem animal, analyzing the oral fluid sample qualitatively to detect the presence of one or more non-naturally occurring drugs, analyzing the oral fluid sample quantitatively to determine concentration of the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal, and identifying the one or more non-naturally occurring drugs in the post-mortem subject or in the live or the post-mortem animal. The detection and quantification in oral fluid is more sensitive and faster than detection and quantification of the non-naturally occurring drugs in blood, urine, bile, and liver tissue collected from the same post-mortem subject.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: August 25, 2020
    Inventor: Amy J. Reisinger
  • Patent number: 10755406
    Abstract: Described herein are methods for co-expression analysis of multiple markers in a tissue sample comprising: computing a heat map of marker expression for each of a plurality of single marker channel images, wherein each of the plurality of single marker channel images comprise a single marker; identifying one or more candidate regions of interest in each heat map of marker expression; computing overlay masks comprising the identified one or more candidate regions of interest from each heat map of marker expression; determining one or more co-localized regions of interest from the overlay masks; mapping the one or more co-localized regions of interest to a same coordinate position in each of the plurality of single marker channel images; and estimating a number of cells in at least one of the determined one or more co-localized regions of interest in each of the plurality of single marker channel images.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 25, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Michael Barnes, Christophe Chefd'hotel, Ting Chen, Shalini Singh, Alisa Tubbs
  • Patent number: 10739347
    Abstract: A bioassay for the detection of multiple target analytes that includes living immunocytes of a plurality of predetermined types; a signal-generating reporter within each immunocyte that is responsive to predetermined changes occurring within the immunocyte and that includes a bioluminescent protein linked to a fluorescent protein; a signal transduction pathway associated with each signal-generating reporter that is operative to induce the predetermined changes within each immunocyte; a detector element associated with the signal transduction pathway that is operative to trigger the signal transduction pathway; an analyte binding element associated with the detector element that is specific to both the detector element and a target analyte; and wherein upon the binding of an analyte binding element to which a target analyte is also bound to the detector element, the detector element triggers the signal transduction pathway causing the predetermined changes to occur within the living biological cell, thereby ca
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: August 11, 2020
    Assignee: Fundamental Solutions Corporation
    Inventors: M. Russell Williams, Joel Lwande, Shengwen Liang, Kyle McQuaid
  • Patent number: 10725052
    Abstract: The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: July 28, 2020
    Inventors: Mahalakshmi Yerramilli, Giosi Farace, John J. Quinn, Murthy V. S. N. Yerramilli
  • Patent number: 10711185
    Abstract: A reagent for performing a chemiluminescent reaction includes luminol or luminol derivatives, an oxidant, an electron mediator, and an enhancer. The enhancer is a nitrogen-containing fused heterocyclic compound having at least two nitrogen atoms. The present disclosure further provides a kit for performing a chemiluminescent reaction comprising the aforesaid reagent.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: July 14, 2020
    Assignee: BIO-HELIX CO., LTD.
    Inventors: Cheng-Yen Lee, Chia-Wen Lien
  • Patent number: 10655163
    Abstract: Described herein are methods, compositions, kits and systems for multiplexed detection of target molecules from a sample. In some embodiments, the methods, compositions, kits and systems can be used to perform multiplexed protein analysis of a sample (e.g., a sample comprising a small number of cells or a single-cell sample). In some embodiments, the same sample subjected to a multiplexed protein analysis using the methods, compositions, kits and systems described herein can also be subjected to a nucleic acid (e.g., RNAs, microRNAs, and/or DNA) analysis, thereby creating an integrated expression profiling from a limited amount of sample.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: May 19, 2020
    Inventors: Ralph Weissleder, Sarit S. Agasti, Vanessa M. Peterson, Adeeti Ullal
  • Patent number: 10656163
    Abstract: The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: May 19, 2020
    Assignee: Wallac Oy
    Inventors: Tarja Ahola, Heikki Kouru, Mikko Sairanen
  • Patent number: 10634671
    Abstract: The invention relates to a method for in situ imaging of samples by cycle multiplexing that enables imaging of various molecular targets through multi-molecular read-outs on the same sample in a rapid, highly sensitive and reliable manner. The invention is further related to imaging buffers preventing the degradation of the sample and of the imaging reagents, which are particularly useful in a method of in situ imaging of samples by cycle multiplexing according to the invention.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: April 28, 2020
    Inventors: Ata Tuna Ciftlik, Diego Gabriel Dupouy, Pierre Joris, Martin Gijs
  • Patent number: 10604699
    Abstract: Provided are an organic rare-earth solid micelle, a preparation method therefor, and a method for increasing the photoelectric conversion efficiency of a solar battery. A small organic conjugated ligand is taken as a first ligand, an amphiphilic diblock polymer is taken as a second ligand, and the first ligand and the second ligand are mixed and doped with a rare-earth chloride solution, and self-assembled to form an organic rare-earth solid micelle, whereby the fluorescence emission intensity and the fluorescence efficiency of the rare-earth element are improved. Next, the prepared organic rare-earth solid micelle is spin coated on an ITO layer of a solar battery, to prepare a solar battery with the organic rare-earth solid micelle. Therefore the sunlight absorption of a cell is increased, and the photoelectric conversion efficiency is improved. The preparation process is simple, low in cost, high in photoelectric conversion efficiency, and environmentally friendly.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: March 31, 2020
    Assignee: Qingdao University
    Inventors: Jianguo Tang, Die Wang, Wenfei Shen, Xinzhi Wang, Yao Wang, Linjun Huang, Jixian Liu, Jiqing Jiao, Yanxin Wang, Wei Wang, Xiaolin Zhang, Fanchen Bu, Jing Wang, Yan Song, Huihui Yang, Xingqin Xu, Laurence A. Belfiore
  • Patent number: 10564151
    Abstract: The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: February 18, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Michael Schraeml, Markus Roessler, Michael Gerg
  • Patent number: 10564084
    Abstract: Disclosed is a process and device allowing for fast measurements of the physicochemical properties of amphiphiles (lipids, surfactants, soaps, . . . ). A Marangoni flow is created and characterized using amphiphiles to be characterized. The observed flow is characterized, and using the disclosed process, one can deduce from this measurement many important physicochemical parameters of the amphiphiles such as their critical micellar concentration. Compared to existing techniques, the disclosed process offers the advantage that it requires a single experiment to deduce the parameters, when other techniques (pendant drop method, conductometry, etc . . . ) require the measurement of a quantity (interfacial tension, conductometry) against a systematically varied parameter (amphiphile concentration, . . . ). The disclosed process and devices are ideal to characterize and/or screen rapidly amphiphiles molecules based on their interaction with a solvent.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 18, 2020
    Inventors: Matthieu Roche, Howard A. Stone, Isabelle Cantat, Arnaud Saint-Jalmes, Ian Griffiths, Sebastien Le Roux, Zhen Zhen Li
  • Patent number: 10514604
    Abstract: Topcoat compositions are provided that are suitably applied above a photoresist composition. Preferred topcoat compositions comprise a first polymer that comprises (i) first units comprising a nitrogen-containing moiety that comprises an acid-labile group; and (ii) second units that (1) comprise one or more hydrophobic groups and (2) are distinct from the first units.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 24, 2019
    Assignee: Rohm and Haas Electronic Materials Korea Ltd.
    Inventors: Chang-Young Hong, Eui-Hyun Ryu, Min-Kyung Jang, Dong-Yong Kim, Jae Yun Ahn
  • Patent number: 10509031
    Abstract: A method for providing quality control on a lateral flow assay device or for triggering a process-related step, the device including a substrate having at least one sample receiving area, at least one reagent zone downstream and in fluid communication with the at least one sample receiving area, at least one detection zone downstream and in fluid communication with the at least one reagent zone and at least one wicking zone downstream of the at least one detection zone, each fluidly interconnected therewith along at least one fluid flow path. The detection material provided in the at least one reagent zone produces a detectable signal that can be tracked and monitored prior to the completion of at least one test being performed on the lateral flow assay device.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 17, 2019
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Zhong Ding, James E. Robinson, David A. Tomasso, David A. Heavner
  • Patent number: 10509046
    Abstract: Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: December 17, 2019
    Assignee: Randox Laboratories Limited
    Inventors: Ivan McConnell, Peter Fitzgerald, Philip Lowry, Elouard Benchikh
  • Patent number: 10494436
    Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 3, 2019
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Carlos Ricardo Rodrigues Dos Reis
  • Patent number: 10466238
    Abstract: The present invention fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of these immunogenic peptides is controlled by immunological assays based on antibodies reactive against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: November 5, 2019
    Inventors: Carolina Sousa Martin, Isabel Comino Montilla, Ana Real Calderon, Santiago Vivas Alegre, Angel Cebolla Ramirez
  • Patent number: RE48862
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 28, 2021
    Assignee: Wyeth LLC
    Inventors: Maninder K. Sidhu, Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint